我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
23
7 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
1942
进行中（未招募）
1
4.3%
已完成
5
21.7%
尚未招募
6
26.1%
招募中
11
47.8%
暂无批准数据
- Australian biotechnology company Inventia Life Science has launched the world's first clinical trial of LIGŌ, a 3D bioprinting device that delivers patients' own cells directly to wound sites without requiring skin grafts. - The LIGŌ device works like an inkjet printer, precisely depositing nano-sized droplets of bioink containing living cells and biomaterials to create a scaffold that supports natural skin regeneration. - Future applications may extend beyond burn treatment to include skin cancer excisions, diabetic ulcers, and potentially regeneration of muscle, cartilage, and cornea tissue, promising reduced hospital stays and healthcare costs.
